236 related articles for article (PubMed ID: 33506914)
1. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
Shuai ZQ; Zhang CX; Shuai ZW; Ge SL
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
[TBL] [Abstract][Full Text] [Related]
2. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis.
Barra L; Yang G; Pagnoux C;
Autoimmun Rev; 2018 Jul; 17(7):683-693. PubMed ID: 29729444
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials.
Singh A; Danda D; Hussain S; Najmi AK; Mathew A; Goel R; Lakhan SE; Tajudheen B; Antony B
Mod Rheumatol; 2021 Jan; 31(1):197-204. PubMed ID: 32000551
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.
Kang L; Liu Y; Luo Z; Zhou Y; Chen B; Yin G; Xie Q
Front Immunol; 2023; 14():1084558. PubMed ID: 36845158
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review.
Li H; Shuai Z
Heart Vessels; 2022 May; 37(5):884-894. PubMed ID: 34750666
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis.
Misra DP; Singh K; Rathore U; Patro P; Tomelleri A; Campochiaro C; Agarwal V; Sharma A
Autoimmun Rev; 2023 Mar; 22(3):103275. PubMed ID: 36652977
[TBL] [Abstract][Full Text] [Related]
7. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.
Misra DP; Rathore U; Patro P; Agarwal V; Sharma A
Clin Rheumatol; 2021 Nov; 40(11):4391-4416. PubMed ID: 33932173
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis.
Misra DP; Rathore U; Patro P; Agarwal V; Sharma A
Rheumatol Int; 2021 Oct; 41(10):1729-1742. PubMed ID: 34302232
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
Pan L; Du J; Liu J; Liao H; Liu X; Guo X; Liang J; Han H; Yang L; Zhou Y
Clin Rheumatol; 2020 Aug; 39(8):2369-2378. PubMed ID: 32144625
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis.
Wen X; Hou R; Xu K; Han Y; Hu J; Zhang Y; Su Y; Gao J; Zhang G; Zhang L
PLoS One; 2021; 16(2):e0245612. PubMed ID: 33529185
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y; Isobe M; Takei S; Tanaka Y; Ishii T; Yokota S; Nomura A; Yoshida S; Nishimoto N
Ann Rheum Dis; 2018 Mar; 77(3):348-354. PubMed ID: 29191819
[TBL] [Abstract][Full Text] [Related]
12. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab.
Alibaz-Oner F; Kaymaz-Tahra S; Bayındır Ö; Yazici A; Ince B; Kalkan K; Kanıtez NA; Kocaer SB; Yasar Bilge NS; Omma A; Durak E; Ilgın C; Akar S; Kaşifoğlu T; Önen F; Emmungil H; İnanç M; Cefle A; Aksu K; Keser G; Direskeneli H
Semin Arthritis Rheum; 2021 Dec; 51(6):1224-1229. PubMed ID: 34706312
[TBL] [Abstract][Full Text] [Related]
13. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
Osman M; Pagnoux C; Dryden DM; Storie D; Yacyshyn E
PLoS One; 2014; 9(12):e115026. PubMed ID: 25517966
[TBL] [Abstract][Full Text] [Related]
14. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tocilizumab for intractable Takayasu arteritis and
Isobe M; Maejima Y; Saji M; Tateishi U
J Cardiol; 2021 May; 77(5):539-544. PubMed ID: 33451862
[TBL] [Abstract][Full Text] [Related]
16. Development of severe colitis in Takayasu arteritis treated with tocilizumab.
Ishii K; Shirai T; Kakuta Y; Machiyama T; Sato H; Ishii T; Harigae H; Fujii H
Clin Rheumatol; 2022 Jun; 41(6):1911-1918. PubMed ID: 35188603
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of biological agents in patients with giant cell arteritis: A meta-analysis of randomized trials.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Sep; 58(9):504-510. PubMed ID: 32567545
[TBL] [Abstract][Full Text] [Related]
18. The comparative safety of biological treatment in patients with axial spondylarthritis: a meta-analysis of randomized controlled trials with placebo.
Sun WT; He YH; Dong MM; Zhang YN; Peng KX; Zhang YM; Lin YD; Yang C; Peng PX
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9824-9836. PubMed ID: 33090385
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
[TBL] [Abstract][Full Text] [Related]
20. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
